Form 4: Ekso Bionics Director Mary Ann Cloyd Reports Acquisition and Disposal of Shares

Director Mary Ann Cloyd reports acquiring and disposing of Ekso Bionics Holdings, Inc. shares, including restricted stock units (RSUs), following the company's annual meeting.

Summary

• Mary Ann Cloyd, a director of Ekso Bionics Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 16, 2025, Cloyd acquired 236,202 shares in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs were granted as part of an automatic annual non-employee director grant provision approved on April 13, 2021.
• The RSUs will vest and settle on the earlier of the next Annual Meeting of Stockholders or one year from the grant date.
• Cloyd also disposed of an unspecified amount of common stock.
• Following these transactions, Cloyd beneficially owns 456,707 shares, including 236,202 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction related to director compensation. There are no explicit positive or negative implications.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The RSUs are scheduled to vest and settle at the earlier of the date of the next Annual Meeting of Stockholders or the one-year anniversary of the Grant Date.

Industry Context

This filing is a routine disclosure related to director compensation and equity ownership, common in publicly traded companies.

Stakeholder Impact

• The RSU grant aligns the director's interests with shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, EKSO, Ekso Bionics, RSU, Restricted Stock Units